"Men"

Almost everyone hopes to have a young and healthy heart. However, 62% of people over 40 years old have cardiovascular disease or risk factors to varying degrees, and 80% of them have not yet fully understood how to maintain a healthy heart. Medical research shows that among all internal organs, the heart is most likely to suffer from "obesity", especially in patients with hypertension, which can also lead to gradual thickening of the heart muscle.

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

Approval for new FIC depression drug on the horizon!

Osteoporosis is the cause of menopausal fractures! Do these 5 things to avoid osteoporosis

Most of the time, uterine cold is caused by too much cold energy in the body.

Leukaemia is a very complex disease that causes fever and infection and bleeding, so it needs to be treated early so that it can be gradually controlled and the patient's symptoms can be gradually relieved

Every September is the "World Alzheimer's Disease Month". In 2022, the theme of "World Alzheimer's Disease Month" is "Know Dementia, Know Alzheimer's - Another, we can do so much". It aims to continue to focus on early screening and early diagnosis, and focus on publicizing the 10 early symptoms, 12 risk factors that can be intervened and medical and social support after diagnosis of Alzheimer's disease, so as to achieve the goal of overall management of Alzheimer's disease

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!